Zbtb7b Defines a Compensatory Mechanism in MASLD-related HCC Progression by Suppressing H19-mediated Hepatic Lipid Deposition

Overview

Journal Physiol Rep

Specialty Physiology

Date 2024 Dec 23

PMID 39714087

Authors

Yinglin Han

Kaimin Wu

Xin Peng

Yinkun Fu

Wenyan Li

Jing Ma

He Jiang

Xu-Yun Zhao

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is a widely prevalent type of primary liver cancer. However, strategies for pretumor intervention are still limited. In this study, a liver-specific Zbtb7b knockout mouse model was used to evaluate the role of Zbtb7b in metabolic dysfunction-associated steatotic liver disease (MASLD)-related HCC development. We revealed that Zbtb7b was compensatively increased and restricted lipid deposition in the liver during MASLD progression, which protects against MASLD-related HCC initiation. Mechanistically, Zbtb7b suppresses the expression of the long noncoding RNA H19 to attenuate hepatic de novo lipogenesis and increase fatty acid oxidation, thereby preventing lipid accumulation in hepatocytes. As a result, the proliferation and migration abilities of HCC cells are reduced. Overall, we demonstrated that Zbtb7b serves as a tumor suppressor at an early stage of HCC, thus providing a promising target for the treatment of HCC at a premalignant stage.

References

He X, He X, Dave V, Zhang Y, Hua X, Nicolas E . The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature. 2005; 433(7028):826-33. DOI: 10.1038/nature03338. View

Bian Z, Xu C, Wang X, Zhang B, Xiao Y, Liu L . TRIM65/NF2/YAP1 Signaling Coordinately Orchestrates Metabolic and Immune Advantages in Hepatocellular Carcinoma. Adv Sci (Weinh). 2024; 11(35):e2402578. PMC: 11425264. DOI: 10.1002/advs.202402578. View

Mariani F, Sena P, Pedroni M, Benatti P, Manni P, Di Gregorio C . Th inducing POZ-Kruppel Factor (ThPOK) is a key regulator of the immune response since the early steps of colorectal carcinogenesis. PLoS One. 2013; 8(1):e54488. PMC: 3547940. DOI: 10.1371/journal.pone.0054488. View

Nakagawa H, Hayata Y, Kawamura S, Yamada T, Fujiwara N, Koike K . Lipid Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers (Basel). 2018; 10(11). PMC: 6265967. DOI: 10.3390/cancers10110447. View

Anwanwan D, Singh S, Singh S, Saikam V, Singh R . Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2019; 1873(1):188314. PMC: 6981221. DOI: 10.1016/j.bbcan.2019.188314. View

Sia D, Villanueva A, Friedman S, Llovet J . Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Gastroenterology. 2017; 152(4):745-761. DOI: 10.1053/j.gastro.2016.11.048. View

Li S, Mi L, Yu L, Yu Q, Liu T, Wang G . Zbtb7b engages the long noncoding RNA Blnc1 to drive brown and beige fat development and thermogenesis. Proc Natl Acad Sci U S A. 2017; 114(34):E7111-E7120. PMC: 5576792. DOI: 10.1073/pnas.1703494114. View

Monroy-Ramirez H, Galicia-Moreno M, Sandoval-Rodriguez A, Meza-Rios A, Santos A, Armendariz-Borunda J . PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases. Int J Mol Sci. 2021; 22(15). PMC: 8347792. DOI: 10.3390/ijms22158298. View

Zhu J, Thompson C . Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019; 20(7):436-450. PMC: 6592760. DOI: 10.1038/s41580-019-0123-5. View

10.

Martinez-Reyes I, Chandel N . Cancer metabolism: looking forward. Nat Rev Cancer. 2021; 21(10):669-680. DOI: 10.1038/s41568-021-00378-6. View

11.

Xia L, Jiang L, Chen Y, Zhang G, Chen L . ThPOK transcriptionally inactivates TNFRSF12A to increase the proliferation of T cells with the involvement of the NF-kB pathway. Cytokine. 2021; 148:155658. DOI: 10.1016/j.cyto.2021.155658. View

12.

Yan J, Zhang Y, She Q, Li X, Peng L, Wang X . Long Noncoding RNA H19/miR-675 Axis Promotes Gastric Cancer via FADD/Caspase 8/Caspase 3 Signaling Pathway. Cell Physiol Biochem. 2017; 42(6):2364-2376. DOI: 10.1159/000480028. View

13.

Ning Z, Guo X, Liu X, Lu C, Wang A, Wang X . USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma. Nat Commun. 2022; 13(1):2187. PMC: 9023467. DOI: 10.1038/s41467-022-29846-9. View

14.

Liu C, Yang Z, Wu J, Zhang L, Lee S, Shin D . Long noncoding RNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis. Hepatology. 2017; 67(5):1768-1783. PMC: 5906152. DOI: 10.1002/hep.29654. View

15.

Chen Y, Jiang L, Xia L, Zhang G, Chen L . ThPOK inhibits the immune escape of gastric cancer cells by inducing STPG1 to inactivate the ERK pathway. BMC Immunol. 2022; 23(1):16. PMC: 8981657. DOI: 10.1186/s12865-022-00485-5. View

16.

Currie E, Schulze A, Zechner R, Walther T, Farese Jr R . Cellular fatty acid metabolism and cancer. Cell Metab. 2013; 18(2):153-61. PMC: 3742569. DOI: 10.1016/j.cmet.2013.05.017. View

17.

Li Y, Pan Y, Zhao X, Wu S, Li F, Wang Y . Peroxisome proliferator-activated receptors: A key link between lipid metabolism and cancer progression. Clin Nutr. 2023; 43(2):332-345. DOI: 10.1016/j.clnu.2023.12.005. View

18.

Wang M, Han J, Xing H, Zhang H, Li Z, Liang L . Dysregulated fatty acid metabolism in hepatocellular carcinoma. Hepat Oncol. 2018; 3(4):241-251. PMC: 6095185. DOI: 10.2217/hep-2016-0012. View

19.

Ringelhan M, Pfister D, OConnor T, Pikarsky E, Heikenwalder M . The immunology of hepatocellular carcinoma. Nat Immunol. 2018; 19(3):222-232. DOI: 10.1038/s41590-018-0044-z. View

20.

Gamaev L, Mizrahi L, Friehmann T, Rosenberg N, Pappo O, Olam D . The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma. Oncogene. 2020; 40(1):127-139. DOI: 10.1038/s41388-020-01513-7. View